| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | saxagliptin/dapagliflozin (Qtern®) |
| Formulation | 5 mg/10 mg film-coated tablet |
| Reference number | 2209 |
| Indication | Treatment of adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin and/or sulphonylurea and one of the monocomponents of Qtern do not provide adequate glycaemic control; when already being treated with the free combination of dapagliflozin and saxagliptin |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 18/07/2017 |